Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase 1b/2 Open-Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)]
Category & Conditions: Cancer
Medicine: sasanlimab
ClinicalTrials.gov Identifier (NCT): NCT04585815
Protocol ID: B8011011
Open Plain Language Summary Result:
Click here